• Wir verstehen, was wir schreiben



URL Links zu den Publikationen:

Machiels, JP., Mazzeo, F., Clausse, et al. Prospective Randomized Study Comparing Docetaxel, Estramustine, and Prednisone With Docetaxel and Prednisone in Metastatic Hormone-Refractory Prostate Cancer. J Clin Oncol 2008; 26: 5261-5268

Personeni, N. Fieuws, S., Piessevaux, H. et al., Clinical Usefulness of EGFR Gene Copy Number as a Predictive Marker in Colorectal Cancer Patients Treated with Cetuximab : A Fluorescent In situ Hypridization Study. Clin Cancer Res 2008;14(18): 5869-5876

Personeni, N. Epidermal Growth Factor Receptor Gene Copy Number in Esophageal Cancer and Outcome Preditction to Gefitinib: Does Intrtumoral Heterogeneity Matter? J Clin Oncol 2006; 24: 5465

Personeni, N. Outcome Prediction to Erlotinib in Gastroesophageal Adenocarcinomas: Can We Improve Epidermal Growth Factor Receptor and Phospho-AKT Testing? J Clin Oncol 2007; 25: 910

Schmitz, S., Daminsky-Forrett, M-C., Henry, S., et al. Phase II study of figitumumab in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck: clinical activity and molecular response (GORTEC 2008-02) Ann Oncol 2012;23(8): 2153-2161 First published online January 10, 2012 doi:10.1093/annonc/mdr574

Schmitz, S., Hamoir, M., Reychler, H., et al. Tumour response and safety of cetuximab in a window pre-operative study in patients with squamous cell carcinoma of the head and neck Ann Oncol 2013;24(9): 2261-2266 First published online May 23, 2013 doi:10.1093/annonc/mdt180

Schmitz, S. et al., Targeted therapies for squamous cell carcinoma of the head and neck: Current knowledge and future directions. Cancer Treat Rev 2013;